Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

June 26, 2024

Journal of Medicinal Chemistry: Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma

Matthew M. Weiss, et al.
Read More
June 14, 2024

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers

European Hematology Association (EHA) 2024
cHL CTCL Liquid Tumors Solid Tumors
Read More
June 1, 2024

Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of KT-253, a Targeted Protein Degrader of MDM2, in Patients with Relapsed/Refractory (R/R) Solid Tumors, Lymphoma, High Grade Myeloid Malignancies and Acute Lymphoblastic Leukemia (ALL)

American Society of Clinical Oncology (ASCO) 2024
Liquid Tumors Solid Tumors
Read More
April 7, 2024

E3 Pairing and Structural Mechanisms Underlying Anti-Tumor Activity of Clinical STAT3 Degrader KT-333

American Association for Cancer Research (AACR) 2024 Annual Meeting
Read More
December 10, 2023

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Hematology (ASH) Annual Meeting and Exposition 2024
CTCL LGL-L PTCL Solid Tumors
Read More
October 16, 2023

Development of KT-253, a highly potent and selective heterobifunctional MDM2 degrader, for the treatment of Acute Myeloid Leukemia

10th International MDM2 Workshop
Liquid Tumors Solid Tumors
Read More
October 14, 2023

The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Solid Tumors
Read More
June 14, 2023

Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

International Conference on Malignant Lymphoma (ICML) 2023
CTCL LGL-L PTCL Solid Tumors
Read More
June 6, 2023

Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors

European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
Read More
December 12, 2022

Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition

American Society of Hematology Annual Meeting and Expo
MYD88 Tumors
Read More